Cory Yeh1, Daniel Bowers, Tessa A Hadlock. 1. Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, 243 Charles St, Boston, MA 02114, USA. cyeh@partners.org
Abstract
OBJECTIVE: To examine the effect of the immunosuppressive agent FK506 on the rate of functional recovery of the rat facial nerve after crush injury. METHODS: Forty rats underwent facial nerve crush injury and were randomly assigned to 4 experimental groups: isotonic sodium chloride solution control, FK binding protein 52 (FKBP-52) antibody control, FK506, and FK506 and FKBP-52 antibody. Rats underwent daily recovery testing from postoperative day 9 until postoperative day 21 by videotaping 3 validated variables in this model: blink reflex return, vibrissial fibrillation loss, and return of vibrissial sweeping symmetry. RESULTS: FK506-treated animals demonstrated improved recovery in all 3 variables compared with control animals. The FK506 and FKBP-52 antibody group demonstrated improved recovery of only the return of the blink reflex. CONCLUSIONS: FK506 accelerated functional recovery of facial nerve function after crush injury. Neuroregeneration was inhibited by FKBP-52 antibody in the rat midface but not the upper face. FK506 may be a viable adjuvant treatment for facial nerve neurapraxic injury.
OBJECTIVE: To examine the effect of the immunosuppressive agent FK506 on the rate of functional recovery of the rat facial nerve after crush injury. METHODS: Forty rats underwent facial nerve crush injury and were randomly assigned to 4 experimental groups: isotonic sodium chloride solution control, FK binding protein 52 (FKBP-52) antibody control, FK506, and FK506 and FKBP-52 antibody. Rats underwent daily recovery testing from postoperative day 9 until postoperative day 21 by videotaping 3 validated variables in this model: blink reflex return, vibrissial fibrillation loss, and return of vibrissial sweeping symmetry. RESULTS:FK506-treated animals demonstrated improved recovery in all 3 variables compared with control animals. The FK506 and FKBP-52 antibody group demonstrated improved recovery of only the return of the blink reflex. CONCLUSIONS:FK506 accelerated functional recovery of facial nerve function after crush injury. Neuroregeneration was inhibited by FKBP-52 antibody in the rat midface but not the upper face. FK506 may be a viable adjuvant treatment for facial nerve neurapraxic injury.
Authors: Robin W Lindsay; James T Heaton; Colin Edwards; Christopher Smitson; Kalpesh Vakharia; Tessa A Hadlock Journal: Arch Facial Plast Surg Date: 2010 May-Jun
Authors: Ingrid J Kleiss; Christopher J Knox; Juan S Malo; Henri A M Marres; Tessa A Hadlock; James T Heaton Journal: JAMA Facial Plast Surg Date: 2014 Mar-Apr Impact factor: 4.611
Authors: Tessa A Hadlock; Sang W Kim; Julie S Weinberg; Christopher J Knox; Marc H Hohman; James T Heaton Journal: JAMA Facial Plast Surg Date: 2013-03-01 Impact factor: 4.611
Authors: A Y Mekaj; S Manxhuka-Kerliu; A A Morina; S B Duci; L Shahini; Y H Mekaj Journal: Eur J Trauma Emerg Surg Date: 2016-05-18 Impact factor: 3.693
Authors: James T Heaton; Christopher J Knox; Juan S Malo; James B Kobler; Tessa A Hadlock Journal: IEEE Trans Neural Syst Rehabil Eng Date: 2013-03-07 Impact factor: 3.802
Authors: James T Heaton; Jeffrey Kowaleski; Colin Edwards; Christopher Smitson; Tessa A Hadlock Journal: Invest Ophthalmol Vis Sci Date: 2009-08-26 Impact factor: 4.799
Authors: Tessa A Hadlock; Jeffrey Kowaleski; David Lo; Susan E Mackinnon; James T Heaton Journal: Plast Reconstr Surg Date: 2010-01 Impact factor: 4.730